News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
486,315 Results
Type
Article (8022)
Company Profile (142)
Press Release (478150)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166744)
Career Advice (302)
Deals (25740)
Drug Delivery (7)
Drug Development (52870)
Employer Resources (14)
FDA (9760)
Job Trends (8567)
News (238202)
Policy (17891)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (490)
Accelerated approval (26)
ADA (18)
Adcomms (1)
Allergies (98)
Alliances (33159)
ALS (113)
Alzheimer's disease (988)
Antibody-drug conjugate (ADC) (286)
Approvals (10423)
Artificial intelligence (341)
ASCO (159)
Autoimmune disease (224)
Automation (29)
Bankruptcy (263)
Belgium (2)
Best Places to Work (6958)
BIO (36)
Biologics (10)
BIOSECURE Act (1)
Biosimilars (116)
BioSpace Insights (17)
Biotechnology (90)
Bispecific (1)
Bladder cancer (140)
Brain cancer (31)
Breast cancer (521)
Cancer (3794)
Cardiovascular disease (227)
Career advice (245)
Career pathing (1)
CAR-T (180)
CDC (1)
CDMO (20)
Celiac Disease (1)
Cell therapy (493)
Cervical cancer (35)
Clinical research (48098)
Collaboration (1292)
Commercialization (3)
Compensation (1540)
Complete response letters (34)
COVID-19 (763)
CRISPR (64)
C-suite (811)
Cystic fibrosis (87)
Data (5917)
Denatured (4)
Depression (107)
Dermatology (71)
Diabetes (363)
Diagnostics (4227)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (161)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (167)
Earnings (73757)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (88183)
Executive appointments (717)
FDA (12529)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (19)
Frontotemporal dementia (24)
Funding (958)
Gene editing (126)
Generative AI (11)
Gene therapy (336)
GLP-1 (295)
Government (948)
Grass and pollen (2)
Guidances (281)
Healthcare (9369)
Hematology (94)
HIV (55)
Huntington's disease (23)
IgA nephropathy (70)
Immunology and inflammation (109)
Immuno-oncology (61)
Indications (164)
Infectious disease (955)
Inflammatory bowel disease (130)
Inflation Reduction Act (4)
Influenza (85)
Intellectual property (265)
Interviews (41)
IPO (12389)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (17)
Kidney disease (46)
Layoffs (59)
Legal (5195)
Licensing (20)
Liver cancer (45)
Longevity (20)
Lung cancer (550)
Lymphoma (259)
Machine learning (29)
Management (3)
Manufacturing (582)
Marketing (8)
MASH (118)
Medical affairs (2)
Medical device (8687)
Medtech (8847)
Mergers & acquisitions (14418)
Metabolic disorders (737)
mRNA (65)
Multiple sclerosis (107)
NASH (4)
Neurodegenerative disease (228)
Neuropsychiatric disorders (40)
Neuroscience (1884)
NextGen: Class of 2026 (3150)
Non-profit (843)
Obesity (234)
Opinion (11)
Ovarian cancer (163)
Pain (179)
Pancreatic cancer (208)
Parkinson's disease (207)
Partnered (12)
Patents (505)
Patient recruitment (534)
Patient selection (4)
Peanut (32)
People (41382)
Peptides (3)
Pharmaceutical (30)
Pharmacy benefit managers (9)
Phase 1 (15525)
Phase 2 (21477)
Phase 3 (14495)
Pipeline (7819)
Policy (18)
Postmarket research (1570)
Preclinical (6560)
Press Release (34)
Prostate cancer (193)
Psychedelics (8)
Radiopharmaceuticals (195)
Rare diseases (595)
Real estate (3024)
Recruiting (6)
Regenerative medicine (5)
Regulatory (15008)
Reports (23)
Research institute (585)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (104)
Series A (165)
Series B (123)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (91)
Sponsored (5)
Startups (2020)
Stomach cancer (3)
Substance use disorders (16)
Supply chain (51)
Vaccines (335)
Venture capital (17)
Weight loss (75)
Women's health (90)
Date
Today (19)
Last 7 days (289)
Last 30 days (1400)
Last 365 days (19042)
2026 (13936)
2025 (19239)
2024 (22990)
2023 (26539)
2022 (34587)
2021 (37150)
2020 (33469)
2019 (23256)
2018 (17468)
2017 (18769)
2016 (17900)
2015 (24264)
2014 (21679)
2013 (18128)
2012 (20222)
2011 (20427)
2010 (20332)
Location
Africa (229)
Alabama (80)
Alaska (2)
Arizona (312)
Arkansas (11)
Asia (17981)
Australia (2109)
California (12431)
Canada (3262)
China (553)
Colorado (504)
Connecticut (428)
Delaware (217)
Europe (24708)
Florida (1871)
Georgia (393)
Hawaii (3)
Idaho (46)
Illinois (734)
India (53)
Indiana (326)
Iowa (16)
Japan (431)
Kansas (104)
Kentucky (32)
Louisiana (27)
Maine (26)
Maryland (1236)
Massachusetts (8139)
Michigan (315)
Minnesota (573)
Mississippi (4)
Missouri (83)
Montana (20)
Nebraska (11)
Nevada (124)
New Hampshire (60)
New Jersey (2719)
New Mexico (12)
New York (2916)
North Carolina (1322)
North Dakota (4)
Northern California (6251)
Ohio (297)
Oklahoma (14)
Oregon (16)
Pennsylvania (2310)
Puerto Rico (24)
Rhode Island (30)
South America (406)
South Carolina (78)
South Dakota (1)
Southern California (5181)
Tennessee (125)
Texas (2030)
United States (40291)
Utah (377)
Vermont (1)
Virginia (159)
Washington D.C. (39)
Washington State (960)
West Virginia (1)
Wisconsin (76)
Wyoming (1)
486,315 Results for "inhibrx inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancer
Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a nearly $4 billion near-term opportunity thanks to the Phase 2 results.
September 8, 2026
·
5 min read
·
Annalee Armstrong
Press Releases
Inhibrx Reports Second Quarter 2026 Financial Results
August 14, 2026
·
8 min read
Press Releases
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
September 6, 2026
·
2 min read
Press Releases
Inhibrx’s INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
September 8, 2026
·
10 min read
Press Releases
Inhibrx Reports First Quarter 2026 Financial Results
May 14, 2026
·
7 min read
Press Releases
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
July 16, 2026
·
5 min read
Press Releases
Inhibrx Announces Participation in Upcoming Scientific Conference
March 3, 2026
·
2 min read
Press Releases
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
June 15, 2026
·
10 min read
Press Releases
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
April 22, 2026
·
9 min read
Press Releases
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
March 20, 2026
·
10 min read
1 of 48,632
Next
